摘要
目的评价脑蛋白水解物注射液治疗老年痴呆的疗效和安全性。方法按照Cochrane系统评价的要求全面检索了PubMed(www.ncbi.nlm.nih.gov/PubMed,由美国生物技术信息中心研制)数据库、中国数字医院图书馆(www.chkd.cnki.net)、中国医学科学院的中国生物医学文献光盘数据库(CBMdisk)、奥地利依比威药品有限公司提供的资料,对符合纳入标准的6篇文献共计802名患者的资料进行了Meta分析。结果发表性偏倚分析显示6篇文献的倒漏斗图是对称的,可以做系统评价;对纳入的各独立研究进行异质性检验,2χ=7.74,P=0.17>0.05,故采用固定效应模型分析(Peto法),结果6篇文献的OR合并=2.36,95%CI为(1.76,3.16),整体效果检验Z=5.74,P<0.000 01,表明脑蛋白水解物注射液与安慰剂比较,疗效的差异有统计学意义,在森林图中,OR合并的95%CI横线落在无效竖线右侧,认为脑蛋白水解物注射液治疗老年痴呆有效。结论从现有的临床证据来看,脑蛋白水解物注射液治疗老年痴呆有效且安全性较高。
Objectives To assess the efficacy and safety of Cerebrolysin for Alzheimer＇s disease. Methods According to Cochrane systematic review requirements, a global search has been conducted including：PubMed （www. ncbi.nlm.nih.gov/PubMed）, CHKD （www.chkd.cnki.net）, CBMdisk, providing the data of EBEWE pharma Ges.mbH Nfg. KG Shanghai Representative Office. Results Six randomized controlled trials, including 802 patients, met the inclusion criteria and meta-analysis was carried out, which fit into criteria. Publication bias analysis displayed that the Funnel plot was symmetric;test for heterogeneity showed x^2=7.74, P=0.17 〉 0.05; method of Peto analysis displayed OR=2.36, 95%CI（1.76-3.16） and test for overall effect showed Z=5.74,P〈0.000 01 ,indicating that the difference in curative effect between Cerebrolysin and placebo possess high significance. In Forest plot, the 95%CI horizontal line of OR dropped to the right side of the invalid upright line,indicating that Cerebrolysin was effective in treating Alzheimer＇s disease. Conclusion Current clinical evidence displayed： efficacy and safety of Cerebrolysin for Alzheimer＇s disease.
出处
《循证医学》
CSCD
2005年第6期341-345,共5页
The Journal of Evidence-Based Medicine
